# Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabidiol-novel-inhibitor-id-1-gene-expression/ > **Published:** 2021-11-23T15:45:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:16:51-04:00 > **Clinical Summary:** Explore cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells and its potential to reduce tumor metastasis. --- Invasion and metastasis of aggressive breast cancer cells to other organs is the final and fatal step during cancer progression. Recently, the Id-1 protein was found to be abnormally overexpressed and to serve as a key promoter of the metastatic potential of cancer cells. More specifically, in a research study using mouse models of this disease, scientists demonstrated that metastatic breast cancer cells became significantly less invasive and less metastatic when Id-1 was downregulated using a technique called “antisense stable transduction”. It is not possible at this point, however, to use antisense technology to reduce Id-1 expression in patients with metastatic breast cancer. Fortunately, more recently cannabidiol (CBD) – a cannabinoid derived from the plant cannabis – has been reported to be able to reduce Id-1 expression. In particular, experimental data suggested that CBD can interfere with the transcription of Id-1 mRNA from Id-1 gene; as a result, it decreases the level of Id-1 mRNA and protein in aggressive human breast tissues, preventing these cells from migrating effectively. Also important is the fact that CBD possesses low-toxicity and no adverse psychological effects. In short, as the first nontoxic agent that can significantly decrease Id-1 expression in metastatic breast cancer cells leading to lowered tumor aggressiveness, CBD represents a promising drug candidate for treating breast cancer. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Anti-invasion Effects of Cannabinoids Agonist and Antagonist on Human Breast Cancer Stem Cells](https://cedclinic.com/cannabinoids-breast-cancer-stem-cells-anti-invasion-effects/) Explore how cannabinoids affect the invasion and metastasis of [breast cancer stem cells](https://cedclinic.com/cannabinoids-breast-cancer-stem-cells-anti-invasion-effects/), complementing cannabidiol's role in cancer research. [Read More](https://cedclinic.com/cannabinoids-breast-cancer-stem-cells-anti-invasion-effects/) [Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.](https://cedclinic.com/cbd-glioblastoma-prevention-preclinical-study-results/) Discover cannabidiol's potential in inhibiting tumor growth in glioblastoma, highlighting its broader anti-cancer properties. [Learn More](https://cedclinic.com/cbd-glioblastoma-prevention-preclinical-study-results/) [Cannabidiol may enhance the effectiveness of immunotherapy in multiple myeloma](https://cedclinic.com/cannabidiol-may-enhance-the-effectiveness-of-immunotherapy-in-multiple-myeloma/) Review evidence on cannabidiol's role in boosting immunotherapy outcomes in multiple myeloma, supporting its therapeutic versatility. [Explore Study](https://cedclinic.com/cannabidiol-may-enhance-the-effectiveness-of-immunotherapy-in-multiple-myeloma/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabidiol%20as%20a%20novel%20inhibitor%20of%20Id-1%20gene%20expression%20in%20aggressive%20breast%20cancer%20cells&url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-novel-inhibitor-id-1-gene-expression%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-novel-inhibitor-id-1-gene-expression%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabidiol%20as%20a%20novel%20inhibitor%20of%20Id-1%20gene%20expression%20in%20aggressive%20breast%20cancer%20cells%20https%3A%2F%2Fcedclinic.com%2Fcannabidiol-novel-inhibitor-id-1-gene-expression%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).